Anti-HIV-1 seroreactivity and HIV transmission route[R1]

Detalhes bibliográficos
Autor(a) principal: Bongertz, Vera
Data de Publicação: 1999
Outros Autores: Guimarães, Monick Lindenmeyer, Costa, M. F. G. Soares da, Santos, Valdiléa Gonçalves Veloso dos, Bastos, Francisco Inácio Pinkusfeld Monteiro, Szwarcwald, Celia Landmann, Derrico, Monica, Dias, Paulo Roberto Telles Pires, Pilotto, Jose Henrique da Silva, João Filho, Esaú Custódio, Morgado, Mariza Gonçalves
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/787
Resumo: Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals.
id CRUZ_466d309c0f654511e05b3461475ce8bf
oai_identifier_str oai:www.arca.fiocruz.br:icict/787
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Bongertz, VeraGuimarães, Monick LindenmeyerCosta, M. F. G. Soares daSantos, Valdiléa Gonçalves Veloso dosBastos, Francisco Inácio Pinkusfeld MonteiroSzwarcwald, Celia LandmannDerrico, MonicaDias, Paulo Roberto Telles PiresPilotto, Jose Henrique da SilvaJoão Filho, Esaú CustódioMorgado, Mariza Gonçalves2010-08-23T16:58:49Z2010-11-04T14:20:09Z2010-08-23T16:58:49Z2010-11-04T14:20:09Z1999BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999.1386-6532https://www.arca.fiocruz.br/handle/icict/787Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals.Research supported by the FIOCRUZ Integrated AIDS Program PIAF, World Bank 063:94, CNPq 520922:95-6 and CNPq:MRC(Canada).Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro Centro de Informação Cientifica e Tecnológica. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Informação Cientifica e Tecnológica Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Informação Cientifica e Tecnológica. Rio de Janeiro, RJ, BrasilUniversidade Estadual do Rio de Janeiro. NEPAD. Rio de Janeiro, RJ, BrasilHospital Geral de Nova Iguaçu. Rio de Janeiro, RJ, BrasilHospital dos Servidores do Estado. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilengElsevier Science B.V.Anti-HIV-1 seroreactivity and HIV transmission route[R1]info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHIVSeroreactivityTransmissionGenotypesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZTEXTLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.txtLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.txtExtracted texttext/plain37624https://www.arca.fiocruz.br/bitstream/icict/787/6/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.txt209dbb840deada7e4ad84c8850f2f8e8MD56ORIGINALLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdfapplication/pdf115488https://www.arca.fiocruz.br/bitstream/icict/787/2/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf822ef0044d528414151cf2fc097db530MD52LICENSElicense.txttext/plain1848https://www.arca.fiocruz.br/bitstream/icict/787/3/license.txt9bb8f65f67107ba6a95f9f2a8ded1f54MD53THUMBNAILLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.jpgLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.jpgGenerated Thumbnailimage/jpeg1971https://www.arca.fiocruz.br/bitstream/icict/787/5/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.jpg5ed5d5af2bc10273beea5568c5ae8814MD55icict/7872023-08-23 13:24:56.324oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-08-23T16:24:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Anti-HIV-1 seroreactivity and HIV transmission route[R1]
title Anti-HIV-1 seroreactivity and HIV transmission route[R1]
spellingShingle Anti-HIV-1 seroreactivity and HIV transmission route[R1]
Bongertz, Vera
HIV
Seroreactivity
Transmission
Genotypes
title_short Anti-HIV-1 seroreactivity and HIV transmission route[R1]
title_full Anti-HIV-1 seroreactivity and HIV transmission route[R1]
title_fullStr Anti-HIV-1 seroreactivity and HIV transmission route[R1]
title_full_unstemmed Anti-HIV-1 seroreactivity and HIV transmission route[R1]
title_sort Anti-HIV-1 seroreactivity and HIV transmission route[R1]
author Bongertz, Vera
author_facet Bongertz, Vera
Guimarães, Monick Lindenmeyer
Costa, M. F. G. Soares da
Santos, Valdiléa Gonçalves Veloso dos
Bastos, Francisco Inácio Pinkusfeld Monteiro
Szwarcwald, Celia Landmann
Derrico, Monica
Dias, Paulo Roberto Telles Pires
Pilotto, Jose Henrique da Silva
João Filho, Esaú Custódio
Morgado, Mariza Gonçalves
author_role author
author2 Guimarães, Monick Lindenmeyer
Costa, M. F. G. Soares da
Santos, Valdiléa Gonçalves Veloso dos
Bastos, Francisco Inácio Pinkusfeld Monteiro
Szwarcwald, Celia Landmann
Derrico, Monica
Dias, Paulo Roberto Telles Pires
Pilotto, Jose Henrique da Silva
João Filho, Esaú Custódio
Morgado, Mariza Gonçalves
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Bongertz, Vera
Guimarães, Monick Lindenmeyer
Costa, M. F. G. Soares da
Santos, Valdiléa Gonçalves Veloso dos
Bastos, Francisco Inácio Pinkusfeld Monteiro
Szwarcwald, Celia Landmann
Derrico, Monica
Dias, Paulo Roberto Telles Pires
Pilotto, Jose Henrique da Silva
João Filho, Esaú Custódio
Morgado, Mariza Gonçalves
dc.subject.en.pt_BR.fl_str_mv HIV
Seroreactivity
Transmission
Genotypes
topic HIV
Seroreactivity
Transmission
Genotypes
description Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals.
publishDate 1999
dc.date.issued.fl_str_mv 1999
dc.date.accessioned.fl_str_mv 2010-08-23T16:58:49Z
2010-11-04T14:20:09Z
dc.date.available.fl_str_mv 2010-08-23T16:58:49Z
2010-11-04T14:20:09Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/787
dc.identifier.issn.pt_BR.fl_str_mv 1386-6532
identifier_str_mv BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999.
1386-6532
url https://www.arca.fiocruz.br/handle/icict/787
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier Science B.V.
publisher.none.fl_str_mv Elsevier Science B.V.
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/787/6/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.txt
https://www.arca.fiocruz.br/bitstream/icict/787/2/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf
https://www.arca.fiocruz.br/bitstream/icict/787/3/license.txt
https://www.arca.fiocruz.br/bitstream/icict/787/5/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.jpg
bitstream.checksum.fl_str_mv 209dbb840deada7e4ad84c8850f2f8e8
822ef0044d528414151cf2fc097db530
9bb8f65f67107ba6a95f9f2a8ded1f54
5ed5d5af2bc10273beea5568c5ae8814
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324688634511360